|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2009.21.8198 on April 20 2009 © 2009 American Society of Clinical Oncology.
CA 19-9 and Lewis Antigens in Pancreatic CancerRockville Centre, NY To the Editor: Berger et al1 report on the relationship between postresection CA 19-9 levels and survival in patients with pancreatic cancer treated with adjuvant chemoradiotherapy in the Radiation Therapy Oncology Group 9704 trial. In this analysis, the authors assigned a CA 19-9 level of 0 to patients whose red cell phenotyping for both Lewis A and B antigens was reported to be negative. They based this decision on a 1987 study by Tempero et al,2 which they interpreted to show that "by definition, [such patients] do not have the ability to secrete CA 19-9 into their serum"1; However, Tempero et al examined, in all, twenty patients, only three of whom were Lewis antigen A and B negative. The fact that none of these three patients had elevated CA 19-9 levels (they were not 0, but 4, 10, and 14) does not prove that all patients who lack Lewis antigens lack the ability to secrete CA 19-9. Referring to a table of binomial distributions tells us that the 95% CI for the proportion of patients with elevated CA 19-9 when none are found in a sample of three is 0% to 71%.3 Our usual statistical guidelines do not even permit us to suggest that Lewis antigen–negative patients are less likely to have high CA 19-9 levels than to have low levels. The zeroing out of Lewis antigen–negative patients is all the more disturbing given the discordance Berger et al1 note between the 34% incidence of such patients in their study and the 5% to 10% incidence in the general population. Berger et al1 appear to have missed an opportunity to further our understanding of the correlation between Lewis antigen blood group and CA 19-9 by failing to replicate the work of Tempero et al2 with adequate quality controls. As a result, they may have confounded the results of their study of the relationship between postresection CA 19-9 levels and survival in pancreatic carcinoma. AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. REFERENCES
1. Berger AC, Garcia M Jr, Hoffman JP, et al: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922, 2008. 2. Tempero MA, Uchida E, Takasaki H, et al: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47:5501–5503, 1987. 3. Diem K, and Lenter C. Scientific Tables, ed 7. Basel, Switzerland: Ciba-Geigy, 1970. p.85.
Related Article
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|